Accelerating Nasal Dosage Form Development from Early-Phase to Clinical Trial Manufacture.

Webinar overview (40 minutes)

Exploring the 5 key stages of the UpperNose development platform, Dr. Richard Johnson, Chief Scientific Officer, discusses the importance of target product selection and its impact on formulation and clinical development.

Key topics covered

• Nasal drug delivery devices
• 5 key stages for accelerating to clinical trial manufacture
• Developing Target Product Profile and Device Selection
• Formulation development and excipient selection
• Use of data for IMPD/IND submissions and the set-up of technical batches and stability studies for clinical development
• Manufacture for Phase 1 clinical trials batches, ICH stability and the importance of release testing
• Achieving Phase II / III scale-up
• Use of spray drying for particle engineering
• An in-depth look at the use of the Alberta Idealised Nasal Inlet (AINI) to evaluate formulation/device performance
• Case study of successful spray drying of a Liposomal Vaccine.

Register for this on-demand webinar to gain insights into nasal dosage form development and how to achieve rapid prototype selection for clinical evaluation and commercial success.